Key result
Bisoprolol-amlodipine combination is linked to target BP achievement in ~88% of patients and decreased cfPWV.
Why the study?
Does a fixed combination of bisoprolol and amlodipine improve blood pressure and arterial stiffness in patients with arterial hypertension and metabolic syndrome?
Observational (n=30)
Does a fixed combination of bisoprolol and amlodipine improve blood pressure and arterial stiffness in patients with arterial hypertension and metabolic syndrome?
A fixed combination of bisoprolol and amlodipine effectively lowers blood pressure and reduces arterial stiffness in patients with hypertension and metabolic syndrome.
Answers are grounded in this paper and cite their sources.
May support BP control and stiffness reduction in metabolic syndrome hypertension; should not yet change practice pending RCTs.
Introduction. Combination therapy is widely used in treatment of patients with arterial hypertension (AH) of high and very high cardiovascular risk. Fixed combinations (FC) of medications are preferable and it is important to develop new effective and safe ones. Organ-protective effects are also significant. Objective. To study antihypertensive effectiveness of new FC of highly selective β-adrenoblocker bisoprolol and calcium antagonist amlodipine (Concor® AM), its influence on cardiometabolic risk factors and target lesions in metabolic disorder patients with AH of stages 1 or 2. Materials and methods. The study included 30 patients (13 male, 17 female, mean age 47.20±0.22 years) with AH of stages 1 or 2 and metabolic syndrome (MS). All patients underwent clinical assessment of blood pressure (BP); levels of serum cholesterol (SCL), high density lipoprotein (HDL), low density lipoprotein (LDL), triglyceride, creatinine, and glucose in oral glucose tolerance test; 24-hour blood pressure monitoring; central systolic blood pressure (CSBP); carotid-femoral pulse wave velocity (cfPWV), and intima-media complex thickness which were determined initially and after 6 months of therapy with FC. Results. The target level of BP was reached by 88% patients after treatment with Concor® AM. Significant deceleration of heart rate (from 74.95±2.20 to 68.81±1.13 bpm) and CSBP (from 151.7 to 132.6 mm Hg) were observed. Treatment with Concor® AM led to artery stiffness decrease evaluated by cfPWV decrease (from 14.21±0.45 to 12.1±0.23 m/s, p≤0.05). Conclusion. FC of highly selective β-adrenoblocker bisoprolol and calcium antagonist amlodipine (Concor® AM) was shown effective for AH treatment in patients with MS. Future research is recommended to investigate the effectiveness of FC therapy in a larger cohort of patients.
No takes yet. Share an insight, caveat, or question.
Zhernakova et al. (2017) conducted an observational in Arterial hypertension (stages 1 or 2) and metabolic syndrome (n=30). Fixed combination of bisoprolol and amlodipine (Concor® AM) was evaluated on Target level of blood pressure. Treatment with a fixed combination of bisoprolol and amlodipine achieved target blood pressure in 88% of patients and decreased carotid-femoral pulse wave velocity.
Synapse has enriched 10 related papers. Consider them for comparative context: